Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas
Pancreatic cancer is resistant to most chemotherapeutic regimens. Based upon evidence of synergy between 5-fluorouracil (5-FU) and cisplatin (CDDP), and of enhanced 5-FU activity in the presence of leucovorin in other neoplasms, a phase II study of CDDP, 5-FU, and leucovorin was conducted to determine the efficacy of this regimen in patients with unresectable adenocarcinomas of the pancreas. Nineteen patients were enrolled, and all were evaluable for toxicity and response. One complete and two partial responses were observed (15.8%). Adverse effects were reversible and tolerable. This regimen has limited activity against pancreatic cancer, and cannot be recommended as standard therapy in this disease.
Jones, DV; Sugarman, SM; Markowitz, AB; Levin, B; Abbruzzese, JL; Evans, DB; Charnsangavej, C; Smith, R; Patt, YZ
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)